For research use only. Not for therapeutic Use.
Tesnatilimab（Cat No.:I042208）is a monoclonal antibody that targets PD-1 (programmed cell death protein 1), a checkpoint receptor on T-cells involved in immune suppression. By blocking the interaction between PD-1 and its ligands (PD-L1/PD-L2), tesnatilimab aims to restore and enhance the immune system’s ability to recognize and attack cancer cells. It is being investigated in clinical trials for its potential in treating a variety of cancers, including non-small cell lung cancer (NSCLC) and solid tumors. Tesnatilimab is being evaluated for safety, efficacy, and its ability to improve patient outcomes when used alone or in combination with other therapies.
| Catalog Number | I042208 |
| CAS Number | 2242758-08-1 |
| Purity | ≥95% |
